Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | STAT1 | P42224 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 5/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2543738 | 0.93 | SMN1; SMN2 (0.42) | LMNASMN1; SMN2PIK3CAUSP2TSHR | |
| SCHEMBL2541005 | 0.88 | ACHE (0.46) | LMNASMN1; SMN2RAB9ASTAT1ACHE | |
| SCHEMBL2541718 | 0.88 | ACHE (0.37) | LMNASMN1; SMN2RAB9ASTAT1ACHE | |
| SCHEMBL2541008 | 0.88 | PIK3CA (0.49) | LMNASMN1; SMN2RAB9ASTAT1ACHE | |
| SCHEMBL2544044 | 0.86 | MET (0.48) | LMNASMN1; SMN2RAB9ASTAT1ACHE | |
| SCHEMBL2541760 | 0.85 | ACHE (0.42) | LMNASMN1; SMN2RAB9ASTAT1ACHE | |
| SCHEMBL2547349 | 0.84 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2RAB9ASTAT1ACHE | |
| SCHEMBL1836576 | 0.83 | ALDH1A1 (0.55) | LMNASMN1; SMN2PIK3CAUSP2TSHR | |
| SCHEMBL2542871 | 0.82 | SMN1; SMN2 (0.43) | LMNASMN1; SMN2RAB9ASTAT1ACHE | |
| SCHEMBL2544871 | 0.82 | CLK1 (0.47) | LMNASMN1; SMN2PIK3CAUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263593-A1 | NOVEL IMIDAZO[1,2-a]PYRIMIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS | TPMT, MET, PAICS | LMNA 4476/4885SMN1; SMN2 2888/4885RAB9A 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.